Welcome to our dedicated page for GSK plc news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK plc stock.
GSK plc (formerly known as GlaxoSmithKline plc) is a leading British multinational pharmaceutical and biotechnology company headquartered in London, England. It ranks among the largest pharmaceutical companies globally by total sales, marking its influence in the industry. GSK’s core business segments include prescription medicines, vaccines, and consumer healthcare products. The company has a strong presence in therapeutic areas such as respiratory, oncology, antiviral treatments, and vaccines.
GSK leverages innovations in science and technology to develop and deliver a range of new treatments. Recent achievements include significant advancements in the development of respiratory therapies and cancer treatments. The company also focuses on combating infectious diseases through its strong vaccine portfolio, which includes vaccines for diseases like shingles, influenza, and hepatitis.
Financially, GSK demonstrates robust performance with consistent revenue growth driven by its diverse product pipeline and strategic market presence. The company engages in joint ventures to expand its reach, notably in the HIV market through its collaboration with ViiV Healthcare.
GSK’s commitment to improving global health is evidenced by its dynamic research and development efforts, strategic partnerships, and innovative product launches. Recent news highlights the company’s collaboration with Elegen and Elsie Biotechnologies, Inc., signifying its ongoing efforts to enhance its product offerings and research capabilities.
Investors and stakeholders can stay informed about GSK’s developments and performance by following the latest company news, financial updates, and product announcements.
GSK has initiated the shipment of its trivalent influenza vaccines, FLULAVAL and FLUARIX, for the 2024-25 flu season across the US. This follows the FDA's licensing and lot-release approval, aligning with WHO's recommendation for the removal of the B/Yamagata strain. The vaccines will contain strains A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Thailand/8/2022 (H3N2)-like virus, and B/Austria/1359417/2021 (B/Victoria lineage)-like virus. GSK anticipates distributing over 36 million doses and the vaccines are suitable for individuals aged six months and older. The CDC underscores annual flu vaccination as the optimal protection against influenza, with vaccination ideally completed by the end of October.
The US FDA has approved GSK's AREXVY for preventing RSV lower respiratory tract disease (LRTD) in adults aged 50-59 at increased risk. Previously, the vaccine was only approved for those 60+. Over 13 million US adults aged 50-59 have medical conditions that heighten their risk of severe RSV outcomes, such as COPD, asthma, heart failure, and diabetes. A phase III trial supported this approval, showing positive immune responses and safety in the targeted age group. GSK has also submitted regulatory filings in Europe, Japan, and other regions. Data from ongoing trials in adults 18+ are expected in H2 2024.
GSK announced updated results from a phase II study evaluating Jemperli (dostarlimab-gxly) for treating mismatch repair deficient (dMMR) locally advanced rectal cancer. The trial, conducted with Memorial Sloan Kettering Cancer Center, showed a 100% clinical complete response (cCR) in 42 patients. The results, presented at the 2024 ASCO Annual Meeting, indicate no evidence of disease with a median follow-up of 26.3 months for the first 24 evaluated patients. The study highlights the potential of Jemperli as a non-surgical, first-line treatment option, addressing the negative impacts of current standard treatments. GSK is also advancing further studies, including AZUR-1 and AZUR-2 clinical trials, to evaluate Jemperli in various colorectal cancers.
GSK announced positive interim results from the DREAMM-8 phase III trial, showing that the combination of belantamab mafodotin, pomalidomide, and dexamethasone (PomDex) significantly reduced the risk of disease progression or death by nearly 50% compared to a standard of care combination in relapsed/refractory multiple myeloma. The median progression-free survival (PFS) was not yet reached at a 21.8-month median follow-up for the belantamab mafodotin combination versus 12.7 months for the bortezomib combination. Additionally, the PFS benefit was observed across all pre-specified subgroups, including high-risk patients. Although a positive trend in overall survival (OS) was noted, it was not statistically significant at this interim analysis. Safety profiles were consistent with known profiles of the individual agents, and common adverse events included neutropenia and ocular symptoms. These findings, presented at the 2024 ASCO Annual Meeting and published in the NEJM, support the potential of belantamab mafodotin in redefining treatment for multiple myeloma at or after first relapse.
FAQ
What is GSK plc?
What are the main therapeutic areas GSK focuses on?
What recent collaborations has GSK engaged in?
How does GSK expand its reach in the HIV market?
Where is the headquarters of GSK located?
What achievements has GSK made recently?
What is the financial condition of GSK?
How can investors stay updated about GSK?
What does GSK's product portfolio include?